Drug intelligence / Profile preview

MM010

Development stage: Preclinical
Lead developer: Mucommune
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

MM010 is a monoclonal antibody in preclinical development by Mucommune, specifically designed to target polyethylene glycol (PEG). PEGylation is a common strategy used to improve the stability and half-life of biopharmaceuticals; however, many patients develop anti-PEG antibodies, a phenomenon known as PEG immunogenicity, which can compromise the safety and efficacy of PEGylated drugs. MM010 is being developed to address these challenges, potentially by neutralizing anti-PEG antibodies or otherwise modulating the immune response to PEGylated products to restore or maintain therapeutic efficacy.

Targets

aPL (Antiphospholipid antibodies)BCR (Immunoglobulin G B Cell Receptor)

Beyond the preview

Go deeper on MM010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MM010.

Explore the full profile